Study on Clinical Features, Treatment Mode and Survival of Bone and Soft Tissue Tumors

Recruiting

• Conditions: Bone and Soft Tissue Tumors; Clinical Features

• Registration Number: NCT05468970
• Lead Sponsor: Henan Cancer Hospital

Brief Summary

It is planned to prospectively collect, collate and report real-world clinical data of BSTS patients treated in our hospital in the next ten years to evaluate the changes in clinical characteristics, treatment patterns and survival information of these patients, in order to provide reference for clinical treatment and research of this type of tumor.

Detailed Description

It is planned to prospectively collect, collate and report real-world clinical data of BSTS patients treated in our hospital in the next ten years to evaluate the changes in clinical characteristics, treatment patterns and survival information of these patients, in order to provide reference for clinical treatment and research of this type of tumor. This study is a single-center, prospective, real-world observational study that plans to enroll all eligible patients. Basic information, treatment methods, and prognostic information of these patients were collected.

Study Timeline

• Study First Submitted: 2022-07-19
• Study First Submitted QC: 2022-07-19
• Study First Posted: 2022-07-21
• Study Start: 2022-08-03
• Status Verified: 2023-08
• Last Update Submitted: 2023-08-31
• Last Update Posted: 2023-09-01
• Primary Completion: 2032-07-31
• Study Completion: 2032-07-31

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 6000

Inclusion Criteria

All ages, male and female.

The pathological diagnosis of BSTS in our hospital was a subtype.

Has received at least one hospitalization in this hospital.

The target lesions could be evaluated according to the efficacy evaluation criteria of solid tumor (RECIST; Version 1.1) Measure diameter changes.

Exclusion Criteria

No definite pathology.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Overall survival	Up to approximately 120months	Pathologically confirmed events leading to death
6/5000 Progression-free survival	Up to approximately 48months	The time from the first use of the treatment to the observation of disease progression

Trial Locations

Locations (1)

Department of Bone and Soft Tissue ,Henan Cancer Hospital; 🇨🇳 Zhengzhou, Henan, China